Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02575404
Recruitment Status : Recruiting
First Posted : October 14, 2015
Last Update Posted : October 28, 2019
Sponsor:
Collaborator:
Galectin Therapeutics Inc.
Information provided by (Responsible Party):
Providence Health & Services

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : October 2020
Estimated Study Completion Date : October 2021